Pipeline

Products

Discovery & POC	Lead Optimization	Assets	Pre-clinical	GMP	Clinical Study	Collaborations

Colorectal Cancer: ATP128

Not disclosed

KISIMA^®

Discovery & POC	Lead Optimization	Assets	Pre-clinical	GMP	Clinical Study	Collaborations

Combination

Synthetic peptides

Neoantigens

Our therapeutic vaccines programmes

ATP128

Our most advanced asset is ATP128, a therapeutic vaccine for the treatment of colorectal cancer.

Colorectal cancer is a leading cause of mortality and provides a significant market opportunity ($11 billion by 2025) for us with few cancer vaccine competitors.

This target is well suited for the self-adjuvanting KISIMA^® immunisation platform which is able to turn a cold tumour into a hot tumour in this programme, promoting the tumour infiltration by immune cells.

ATP128 is expected to enter phase I clinical trials in 2019.

Partnering opportunities for ATP128

Other programmes

Our other therapeutic vaccine programmes include one oncology programme in pre-clinical stage. AMAL also plans to expand its development to infectious diseases.